A Phase 2 interventional study of Mesenchymal stromal cell low dosage-80*10^6 cells and Mesenchymal stromal cell low dosage-160*10^6 cells in Traumatic Brain Injury With Loss of Consciousness, sponsored by Fondazione IRCCS San Gerardo dei Tintori. Recruiting at 3 sites in Italy. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-12-11.
Sponsored by Fondazione IRCCS San Gerardo dei Tintori · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 151 studies in Inflammation with a site in Italy — 30 open to participants now, 43 under way, 2 of them phase 3. Inflammation · Italy.
Among the 151 studies in Inflammation with a site in Italy, this one is the 52nd largest by planned enrollment of the 101 interventional ones that give a count, is one of 12 that started in 2023, is one of 14 in phase 2, reaches primary completion later than 5 of the 42 other live ones, and was the 106th registered.
3,544 studies on the registry are indexed under Inflammation; 650 are open to participants now.
Browse Inflammation studies →30 of the 151 studies in Inflammation with a site in Italy are open now. Recruiting first, the newest first:
University of Turin, Italy · Sites in Italy
Ages 18–60
University of Bologna · Sites in Italy
Ages 18+
Mario Negri Institute for Pharmacological Research · Sites in Italy
Ages 55+
IRCCS Centro San Giovanni di Dio Fatebenefratelli · Sites in Italy
Ages 50–80
Federico II University · Sites in Italy
Ages 18–85
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 464 Inflammation studies recruiting now, 175 (38%) set no upper age limit and 208 (45%) stop at 75 or younger; 58 take children under 18; 166 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
151 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 19 · Phase 3 20 · Phase 4 15
First in 1997; this study’s year is marked. 12 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 78 is above the median of 50 across 2,586 interventional studies indexed under Inflammation.
Median enrollment 80 across the 101 interventional studies, 130 across the 50 observational. Of the 87 that completed or were terminated, 10 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 151 have an industry lead sponsor. The 10 most frequent:
Fondazione IRCCS San Gerardo dei Tintori is the lead sponsor of 11 studies on the registry; 9 are open to participants now.
Fondazione IRCCS San Gerardo dei Tintori has 1 study filed under Inflammation — fewer than ten, so there is no comparison to draw.
10 of the studies in Inflammation with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06965023Azienda Ospedaliera "Sant'Andrea"Microplastics and Nanoplastics (MNPs) in Patients With ST-elevation Myocardial Infarction (STEMI) | 2026-12-30 |
| NCT07330869Città di Lecce Hospital, GVM Care & ResearchWarfarin Effects on Male Fertility After Cardiac Surgery | 2027-02 |
| NCT06927739AbcentraFocused Orticumab Research for Treating Inflammation in Coronary Arteries | 2027-02-08 |
| NCT07314684Federico II UniversityGLP1-RAs Effects on Inflammatory and Endothelial Biomarkers in T2DM | 2027-03-08 |
| NCT07331103Mario Negri Institute for Pharmacological ResearchRESOLving INflammation Through Diet for Health (RESOLVIN) | 2027-03-30 |
Add all 10 to your calendar (.ics) → With an account.
Among the 151 studies in Inflammation with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Traumatic Brain Injury (TBI) is an alteration of brain function caused by an external force. Long-term mortality in TBI is substantial, TBI survivors can develop chronic progressive disabilities and have a life expectancy shortened by 6 years. Treatment consists in supportive therapy directed at prevention of second insults, but no neuroprotective therapy is available. Given the multifaceted nature of TBI, mesenchymal stromal cells (MSCs) are an ideal candidate: they release multiple soluble factors shown to ameliorate the injury microenvironment through immunomodulatory, protective, reparative and regenerative processes. Preclinical data across a range of different TBI models and injury severities show that human MSCs improve outcome through pleiotropic mechanisms of protection and repair. Thus, data indicate MSCs as strong therapeutic candidate and support a clinical study in TBI.
Aim: the study is designed to assess the safety and the efficacy of the MSCs, intravenously administered in severe TBI patients within 48h from injury. The study will be conducted in a stepwise manner. Step 1 will enroll 36 patients (randomized 1:1:1 in arms 80 x 10\^6 MSCs vs 160 x 10\^6 MSCs vs placebo) to define safety, and will allow to select the most promising dose. Step 2 will enroll 30 patients (1:1 in arms MSCs selected dose vs placebo) to define the MSC activity based on the quantification of the plasmatic levels of the neurofilament light (NFL) at 14 days, as biomarker of neuronal damage.
Secondary objectives are aimed to assess:
Methods: a multicenter, double blind, randomized, placebo-controlled, adaptive phase II dose finding study.
Duration of the study: 36 months (24 of enrolment and 12 of follow up).
Funding: Fondazione Regionale per la ricerca Biomedica, FRRB (Call "Unmet medical needs", proposal number 3440227) and Italian Ministry of health (Ministero della Salute, Bando di Ricerca Finalizzata 2021; proposal number RF-2021-12372642).
Study Description: Multicenter, double blind, randomized, placebo-controlled, adaptive phase II dose finding study meant to define if MSCs, administered at dosage of 80 or 160 x 10\^6 cells within 48h from TBI, are safe in patients with severe TBI, and to define if MSCs, administered at the dosage found to be safe and more promising, decrease the plasmatic neurofilament light (NFL) biomarker of brain damage at 14 days. Patients will be recruited at the Neurointensive Care Unit at Fondazione IRCCS San Gerardo dei Tintori, Monza, at ASST Ospedale Papa Giovanni XXIII Bergamo and at Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico of Milano. Collection of multiple clinical, neuroimaging and biological parameters will describe TBI evolution.
Preclinical studies: Studies in rodent TBI models have shown that administration of MSCs produces functional improvement with amelioration of sensorimotor and cognitive deficit, reduction of contusion volume and neuronal loss, modulation of the inflammatory response with decreased inflammation, stimulation of beneficial endogenous mechanisms (angiogenesis, neurogenesis, synaptic plasticity). These results support the notion that MSCs can reprogram the microenvironment mitigating the progression of brain damage and fostering recovery of function. Only few clinical studies have assessed the safety, feasibility and efficacy of MSC therapy. No adverse events (AEs) or severe adverse events (SAEs) were reported. No AEs were associated to the intravenous route, which is the one the investigators propose for the study.
Target Sample Size:The total number of evaluable patients to be analyzed will be 66 (27 on the control arm, 12 in the experimental arm stopping at first step and 27 in the experimental arm reaching the second step). In details, the total number of evaluable patients to be analyzed will be 24 (12 patients in each experimental arm) for the safety interim analysis and 54 for the final efficacy analysis (27 patients in both the control arm and in the experimental arm reaching the second step).
Expecting a 13% of deaths of TBI patients in ICU, the number of patients to be randomized is about 78 (32 in the control arm, 14 in the experimental arm stopping at first step and 32 in the experimental arm reaching the second step). In case of the trial closure after the first step, the number of patients to randomize will be about 42 (14 in each arm).
Statistical design and sample size:The statistical study design is conceived in 2 steps.
Step 1: An interim safety analysis will be performed to evaluate separately in each of the two experimental dosage groups, at one-sided type I error rate of 10%, whether more than 30% of patients experience at least one serious adverse drug reaction (SADR) within 14 days from treatment, and at the same time at a power of 80% whether 5% or less of the patients do not experience any SADR. Adopting the Fleming design with A'Hern's approach, 12 evaluable patients will be analyzed in each group (36 patients overall). The maximum number of patients experiencing at least one SADR to observe in each experimental group is 1 out of 12, since this result is associated with an upper limit of the 80% exact confidence interval of 28.8%.
The experimental treatment will be considered as safe for this step only if none or one patient experiment a SADR.
According to the above role:
This cut-off has been defined based on longitudinal quantification kindly provided by BIO-AX-TBI collaborators, showing a median increase of 12.8-fold at 14 days compared to baseline, with first quartile equal to 5-fold increase (see paragraph 5.4 for details). In case of an equal number of responder patients in the two experimental arms, the cut-off defining the response will be increased by 1 unit iteratively since a difference between the two experimental arms will be observed. This assessment will only be performed on the MSC treated arms; the control group will not be considered. According to Simon, Wittes and Ellemberg randomized phase II design, the study has more than 80% probability of correctly select the more active schedule when the proportion of responder patients is 15% higher in the first of the two schedules of treatment.
Step 2: the primary endpoint will be the NFL at 14 days. The final efficacy analysis will be performed by increasing the sample size to 27 evaluable patients in the experimental and control arms. The study is designed to detect an effect size of 0.59 on logarithmic scale of the experimental to control arm, setting a one-sided type I error rate of 10% and a power of 80%.
Data will be analysed by the study biostatistician using the software SAS 9.4 release. A full Statistical Analysis Plan will be written prior to statistical analysis.
Deceased or lost to follow-up patients and patients with missing values will contribute to the analysis of the secondary outcomes only for the time during which data are available.
All patients who have received the treatment will be included in the safety analysis. Each patient will be analyzed in the arm actually received.
The assessment of safety will be mainly based on adverse reactions (ARs) and the frequency and nature of the serious adverse events (SAEs) and will be conducted on the safety analysis set.
Expected results: the investigators expect to prove the safety and efficacy of MSC intravenous administration in acute and severe TBI patients. The investigators will provide a detailed longitudinal description of the effects of MSCs on brain advanced neuroimaging trajectories, on axonal damage and neuro-immunomodulatory changes by blood biomarker analysis and on clinical outcome.
MSC preparation: The preparation of MSCs will be performed as detailed in the IMP brochure according to Good Manufacturing Procedures (GMP) guidelines at Laboratorio Stefano Verri, ASST MONZA. Laboratorio Stefano Verri has standard operating procedures in place for storage, release, thawing, preparing and administering the MSCs.
MSCs are stored in vials containing 40 X 10\^6 MSCs each in 4.5 ml of storage solution (2.5 ml albumin 20%, 1.1 ml normal saline solution, 0.45 ml citrate-dextrose solution (ACD), 0.45 ml Dimethyl sulfoxide (DMSO)). Vials containing 4.5 ml of storage solution only will be prepared and stored in the same manner. The MSC injections and the placebo injections will have identical appearance and consistency. Vials are stored in the vapor phase of liquid nitrogen until the time of administration.
The study treatment will be prepared by qualified personnel under a class A laminar flow hood in proximity to the ICU.
IMP will be administered acutely (within 48h after injury) within 15 minutes from the preparation through a central venous line.
Random allocation procedure: Patients will be randomly assigned to one of the three treatment groups (allocation ratio 1:1:1 for the first step and 1:1 for the second step). The study biostatistician will prepare the sequence of treatments according to a randomized permuted blocks procedure. The randomization schedule will be generated using SAS 9.4 release. The randomized allocation of treatment will be centralized.
Upon recruitment of a patient meeting the inclusion criteria, the local investigator will follow a randomization list (provided by the factory member's personnel) (detailed in the Manual of Procedures) to assign the treatment to the patient in a blinded fashion manner.
Blinding: The subjects, the research coordinators and investigators, and the personnel involved in outcomes assessments and monitoring compliance will all be blinded. Treatment assignment will be known only to the Sponsor Data Management Team and the Cell Factory of each center. An unblinded physician will be designated to monitor safety results.
Patient withdrawal: Patients may withdraw (or be withdrawn) from the study at any time. Withdrawals within 14 days will be replaced.
Reasons for patient withdrawal include:
The risks associated with the intravenous administration procedure include bleeding, swelling and minor pain on injection. These are self-limiting and do not pose any long-term problem.
During the first few hours from the MSC intravenous infusion: headache, fever, rush and allergic reaction may appear. The risk of allergic reaction is mitigated by the use of human platelet lysate instead of the fetal calf serum during the manufacturing process. This also allows to avoid the possible transmission of still unknown zoonosis.
There is also a remote infectious risk that can be treated with appropriate antibiotics. The infection may conduct pain, discomfort and tissue damage.
A possible risk of intravenous MSC infusion is represented by thromboembolic events. MSC infusion could increase pulmonary vascular resistance in the presence of injured pulmonary microcirculation, potentially by aggregating or clumping in capillaries or small arterioles. Subsequent potential risks are acute right heart failure, impaired cardiac output and hemodynamic instability. Additionally, infusion of MSCs could potentially worsen ventilation-perfusion mismatch and result in further impairment of oxygenation or carbon dioxide excretion.
Collection of Data: All data obtained during this clinical trial will be captured electronically in a project specific programmed Electronic Data Capture (EDC) application.
For each subject, all data and trial-related visits will be recorded in the eCRF (electronic Case Report Form). If a subject withdraws from the trial, the reason must be stated in the eCRF.
Informed consent: It is the responsibility of the investigator/delegate to obtain informed consent according to ICH-GCP and Declaration of Helsinki guidelines and local regulations from each individual subject participating in this study and/or his/her legally designated representative/proxy. If the subject is not able to provide personal consent at the time the consent is obtained, then he/she must provide or withdraw this consent as soon as possible once his/her clinical condition has improved to the extent that providing personal consent is possible, unless local regulations state otherwise.
The informed consent form (ICF) will be provided in the country's local language(s).
Regulatory and Ethical Compliance: The trial will be performed in accordance with the Declaration of Helsinki and the Good Clinical Practice. The trial obtained the Regulatory Agency (AIFA) approval. The protocol and trial conduct will comply with the Medicines for Human Use (Clinical Trials) Regulations 2004 and any relevant amendments. Development Safety Update Reports will be submitted to the IEC and Regulatory Agency.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Pre-existing and severe:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Administration: once (bolus), intravenous, 36mL
Other: Placebo-storage solution
Administration: once (bolus), intravenous, 36mL
Drug: Mesenchymal stromal cell low dosage-80*10^6 cells
Administration: once (bolus), intravenous, 36mL
Drug: Mesenchymal stromal cell low dosage-160*10^6 cells
MSCs have to be administered at the dosage of 80\*10\^6. MSCs have to be administered by intravenous infusion via an in situ venous catheter within 15 minutes from the preparation and within 48 hours from TBI. They have to be diluted 1:2 in a saline solution for a total of 36mL.
Also known as: MATRIx MSC low dose
MSCs have to be administered at the dosage of 160\*10\^6. MSCs have to be administered by intravenous infusion via an in situ venous catheter within 15 minutes from the preparation and within 48 hours from TBI. They have to be diluted 1:2 in a saline solution for a total of 36mL.
Also known as: MATRIx MSC high dose
Placebo has to be administered by intravenous infusion via an in situ venous catheter within 15 minutes from the preparation and within 48 hours from TBI. It has to be diluted 1:2 in a saline solution for a total of 36mL.
Also known as: MATRIx placebo
safety of mesenchimal stromal cell intravenous administration in TBI patients
number of patients in each of the two experimental dosage group experiencing at least one serious adverse drug reaction (SADR) (assessed by CTCAE v5.0) within 14 days from treatment. The maximum number of patients experiencing at least one SADR to observe in each experimental group is 1 out of 12.
Time frame: 14 days from treatment administration
efficacy of mesenchimal stromal cells in preventing subacutely post-TBI brain axonal injury
number of MSC-treated patients who reach a plasmatic NFL (neurofilament light) increase at 14 days post-treatment equal or lower than 5-fold compared to the baseline (these patients are defined as "responder patients")
Time frame: 14 days post-TBI
efficacy of mesenchimal stromal cells in preventing post-TBI brain anatomical injury
number of MSC-treated patients that show an improvement in terms of atrophy, diffusion and myelin integrity detected by longitudinal advanced MRI performed acutely (at 4 days post-TBI), subacutely (at 14 days) and at 6 months post-TBI.
Time frame: 4 days post-TBI, 14 days and 6 months
efficacy of mesenchimal stromal cells in preventing the plasmatic increase of TBI-related circulating biomarkers
number of patients who have decreased values of markers related to axonal damage (NFL, GFAP), neuroinflammation (IL-6, IL-10, TNFa) and vascular damage (MMP9) evaluated daily for 3 days after TBI, at day 7 and 14, and at 1, 6 and 12 months
Time frame: daily for 3 days after TBI, at day 7 and 14, and at 1, 6 and 12 months
efficacy of mesenchimal stromal cell administration in improving the clinical outcome of TBI patients
number of patients with an improved clinical and neuropsychological outcome at both 6 and 12 months evaluated by the administration of structured clinical and neuropsychological questionnaires (Glasgow Outcome Scale Extended (GOSE) and quality of life after brain injury test (QOLIBRI)).
Time frame: 6 and 12 months post-TBI
Plan to share: No
Started Sep 2023 (actual). Primary completion is estimated for Dec 2024, 15 months after the start.
Of 113 non-industry phase 2 interventional studies under Inflammation, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 64. This study's planned 15 months is below that.
Counting every sponsor, half of 149 studies reached it within 29 months; a quarter within 16 and three quarters within 56.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fondazione IRCCS San Gerardo dei Tintori